Form 4: ImmunityBio Director Receives Stock Option Grant

Director Christobel Selecky was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.

Summary

• Director Christobel Selecky received a grant of 65,600 stock options on June 9, 2026.
• The options have an exercise price of $7.25 per share.
• The options are scheduled to vest in full on June 9, 2027, or the day before the next annual meeting of stockholders, whichever occurs first.
• The options expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company fundamentals.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the director remaining a Service Provider to the company.

Future Outlook

The options vest in one year, contingent on continued service, indicating a retention-based incentive structure.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is a common governance practice for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 9, 2027.

Key Dates

Keywords

ImmunityBio, IBRX, Director Compensation, Stock Options, Equity Incentive Plan, Insider Transaction